Lynparza Approved in the US as Adjuvant Treatment for Patients with Germline BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer

First and only approved medicine targeting BRCA mutations in early breast cancer New data show Lynparza demonstrated overall survival benefit in early breast cancer March 11, 2022 — AstraZeneca and MSD’s Lynparza…Original Article